564 related articles for article (PubMed ID: 36116461)
1. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
Wassil J; Sisti M; Fairman J; Davis M; Fierro C; Bennett S; Johnson D; Migone TS; Nguyen K; Sauer P; Currie M; Iki S; Simon JK
Lancet Infect Dis; 2024 Mar; 24(3):308-318. PubMed ID: 38061367
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
7. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
8. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
[TBL] [Abstract][Full Text] [Related]
10. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
15. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
18. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
19. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J;
Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
